Bailard Inc. Lowers Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Bailard Inc. decreased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 12.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,500 shares of the company’s stock after selling 900 shares during the period. Bailard Inc.’s holdings in Janux Therapeutics were worth $348,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Plato Investment Management Ltd boosted its position in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares during the period. Rhumbline Advisers lifted its position in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after buying an additional 599 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock valued at $596,000 after buying an additional 1,095 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after buying an additional 2,419 shares during the period. Institutional investors own 75.39% of the company’s stock.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,668 shares of company stock worth $2,577,515 over the last three months. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics Trading Down 5.8 %

Janux Therapeutics stock opened at $29.99 on Wednesday. Janux Therapeutics, Inc. has a 12 month low of $29.63 and a 12 month high of $71.71. The stock has a fifty day simple moving average of $42.72 and a two-hundred day simple moving average of $47.78. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -25.63 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of recent research reports. Scotiabank lowered their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Leerink Partners lifted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research note on Monday. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Finally, William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $88.00.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.